StratDeck

Two stocks in Healthcare

Merck KGaA vs Novartis: profit, growth, debt and price compared

Merck KGaA is stronger on 4 of 7 figures: sales growth, debt, analysts' view and price trend. Novartis is stronger on 3: profit margin, price for its expected profit and dividend.

Figures as of 18 November 2026Yahoo Finance
Explore Merck KGaA's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Merck KGaA and Novartis side by side
Merck KGaAMRK.DENovartisNOVN.SW
Net margin8.9%Stronger: 17.5%
Revenue growth, past yearStronger: +5.80%+4.70%
Debt to equityStronger: 38.1%128.6%
Forward P/E16.4×Stronger: 15.9×
Dividend yield1.47%Stronger: 2.78%
AnalystsStronger: Buy · 14Hold · 22
From its 200-day averageStronger: +11.7%+9.2%

Share price over the past year

  • Merck KGaA+35.2%
  • Novartis+30.9%

20 Nov 202518 Nov 2026

Merck KGaA or Novartis: which is stronger?

  • NOVN.SW

    Which is more profitable?

    Novartis keeps more of each sale as profit: 17.5% against 8.9%.

  • MRK.DE

    Which is growing its sales faster?

    Merck KGaA is growing its sales faster: +5.80% over the past year, against +4.70%.

  • MRK.DE

    Which has borrowed less?

    Merck KGaA has borrowed less: its debt is 38.1% of what its shareholders own, against 128.6% for Novartis.

  • NOVN.SW

    Which costs less for the profit it is expected to make?

    Novartis costs less for the profit it is expected to make: 15.9× its forward earnings, against 16.4×.

  • NOVN.SW

    Which pays more in dividends?

    Novartis pays more back in dividends for what a share costs: 2.78% a year, against 1.47%.

  • MRK.DE

    Which do analysts rate higher?

    Analysts are warmer on Merck KGaA: Buy, against Hold for Novartis.

  • MRK.DE

    Which is in the stronger price trend?

    Merck KGaA's price is in the stronger trend: 11.7% above its 200-day average, against 9.2% above.

What each company does

MRK.DEMerck KGaA

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.

Reports results on 4 March 2027

NOVN.SWNovartis

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

Reports results on 3 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.